NCT03217669: Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

NCT03217669
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Misc Inhibitor, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase
Exclusions: 
https://ClinicalTrials.gov/show/NCT03217669

Comments are closed.

Up ↑